Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY 2
2021-004026-30Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reteplase in catheter-related thrombosis (CRT), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Primary efficacy endpoint. Started Dec 2021; status: terminated.
02
Drugs
reteplase
03
Conditions
catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on 2021-004026-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004026-30.